<p><strong>InterBioTech </strong></p><p>FT-XLS250 </p><p><strong>Entecavir </strong></p><p><strong>Product Description </strong></p><p><strong>Catalog #: </strong></p><p>XLS250, 5mg&nbsp;XLS251, 10mg&nbsp;XLS252, 50mg XLS253, 100mg </p><p>AXAIV0, 1ml 10mM in DMSO. </p><p><strong>Catalog #: Name: </strong></p><p><strong>Entecavir</strong>, Monohydrate </p><p>Syn: BMS200475 monohydrate; SQ34676 monohydrate </p><p>CAS : 209216-23-9 </p><p><strong>MW : </strong></p><p>295.29 </p><p><strong>Formula : Properties: </strong></p><p>C<sub style="top: 0.05em;">12</sub>H<sub style="top: 0.05em;">17</sub>N<sub style="top: 0.05em;">5</sub>O<sub style="top: 0.05em;">4 </sub></p><p>DMSO : ≥ 50 mg/mL (169.33 mM) </p><p>H2O : 2.8 mg/mL (9.48 mM) &gt;99.5% <br>Also available: </p><p><strong>Storage: </strong></p><p>Powder: -20°C (longterm; possible at +4°C (2 years)<sup style="top: -0.25em;">(M) </sup>In solvent: -80°C (6 months)&nbsp;-20°C (1 month) </p><p><strong>Entecavir </strong>free form #RO893P/Q/R </p><p>(Syn.:BMS200475;SQ34676) </p><p>CAS No. : 142217-69-4; MW: 277.2 For Research Use Only </p><p><strong>Introduction </strong></p><p>Entecavir monohydrate(BMS200475 monohydrate; SQ34676 monohydrate)is a potent andselective inhibitorof HBV, with an EC50 of 3.75 nM in HepG2 cell. </p><p>IC50 &amp; Target&nbsp;EC50：3.75 nM (anti-HBV, HepG2 cell)[1] </p><p><strong>In Vitro </strong></p><p>*Solubility : </p><p>DMSO : ≥ 50 mg/mL (169.33 mM) </p><p>H<sub style="top: 0.05em;">2</sub>O : 2.8 mg/mL (9.48 mM; Need ultrasonicandwarming) <br>*Preparation :&nbsp;1mM = 1mg in 3.3865 mL </p><p>Entecavir monohydrate(BMS200475 monohydrate; SQ34676 monohydrate)has a EC50 of 3.75 nM againstHBV. It is incorporated intothe proteinprimer of HBV and subsequently inhibits theprimingstepof the reverse transcriptase. The antiviral activity of BMS-200475 is significantlyless against theother RNA and DNA viruses<a href="Innaimo%20SF,%20et%20al.%20Identification%20of?BMS-200475?as%20a%20potent%20and%20selective%20inhibitor%20of%20hepatitis%20B%20virus.%20Antimicrob%20Agents%20Chemother.%201997%20Jul;41(7):1444-8." target="_blank">[</a><a href="Innaimo%20SF,%20et%20al.%20Identification%20of?BMS-200475?as%20a%20potent%20and%20selective%20inhibitor%20of%20hepatitis%20B%20virus.%20Antimicrob%20Agents%20Chemother.%201997%20Jul;41(7):1444-8." target="_blank">1</a>]. Entecavir monohydrateis more readilyphosphorylatedto its active metabolites than otherdeoxyguanosine analogs (penciclovir, ganciclovir, lobucavir, and aciclovir) or lamivudine. The intracellular half-life of entecavir is 15 h<a href="Rivkin%20A,%20et%20al.%20A%20review%20of%20entecavir%20in%20the%20treatment%20of%20chronic%20hepatitis%20B%20infection.%20Curr%20Med%20Res%20Opin.?2005%20Nov;21(11):1845-56." target="_blank">[</a><a href="Rivkin%20A,%20et%20al.%20A%20review%20of%20entecavir%20in%20the%20treatment%20of%20chronic%20hepatitis%20B%20infection.%20Curr%20Med%20Res%20Opin.?2005%20Nov;21(11):1845-56." target="_blank">2</a>]. </p><p>P.1 </p><p><strong>InterBioTech </strong></p><p>FT-XLS250 </p><p><strong>In Vivo </strong></p><p>*Preparation : 1. Add each solventone by one:&nbsp;10% DMSO&nbsp;40% PEG300&nbsp;5% Tween-80&nbsp;45% saline </p><p>Solubility: ≥ 3 mg/mL (10.16 mM); Clear solution </p><p>2. Add each solventone by one:&nbsp;10% DMSO&nbsp;90% (20% SBE-β-CD in saline) <br>Solubility: ≥ 3 mg/mL (10.16 mM); Clear solution <br>3. Add each solventone by one:&nbsp;10% DMSO&nbsp;90% corn oil </p><p>Solubility: ≥ 3 mg/mL (10.16 mM); Clear solution </p><p>Daily oral treatmentwith Entecavir monohydrateat doses rangingfrom 0.02to 0.5 mg/kgof body weightfor 1 to 3 months effectively reduces thelevel of woodchuck hepatitisvirus (WHV) viremia in chronicallyinfected woodchuck<a href="Genovesi%20EV,%20et%20al.%20Efficacy%20of%20the%20carbocyclic%202'-deoxyguanosine%20nucleoside?BMS-200475?in%20the%20woodchuck%20model%20of%20hepatitis%20B%20virus%20infection.%20Antimicrob%20Agents%20Chemother.?1998%20Dec;42(12):3209-17.More:%20%09•J%20Exp.Clin%20Cancer%20Res.%202019%20Aug%2022;38(1):370.%20%09•J%20Infect.%202019%20Jun%2018.%20pii:%20S0163-4453(19)30187-2." target="_blank">s</a><a href="Genovesi%20EV,%20et%20al.%20Efficacy%20of%20the%20carbocyclic%202'-deoxyguanosine%20nucleoside?BMS-200475?in%20the%20woodchuck%20model%20of%20hepatitis%20B%20virus%20infection.%20Antimicrob%20Agents%20Chemother.?1998%20Dec;42(12):3209-17.More:%20%09•J%20Exp.Clin%20Cancer%20Res.%202019%20Aug%2022;38(1):370.%20%09•J%20Infect.%202019%20Jun%2018.%20pii:%20S0163-4453(19)30187-2." target="_blank">[</a><a href="Genovesi%20EV,%20et%20al.%20Efficacy%20of%20the%20carbocyclic%202'-deoxyguanosine%20nucleoside?BMS-200475?in%20the%20woodchuck%20model%20of%20hepatitis%20B%20virus%20infection.%20Antimicrob%20Agents%20Chemother.?1998%20Dec;42(12):3209-17.More:%20%09•J%20Exp.Clin%20Cancer%20Res.%202019%20Aug%2022;38(1):370.%20%09•J%20Infect.%202019%20Jun%2018.%20pii:%20S0163-4453(19)30187-2." target="_blank">3</a>]. </p><p><strong>References </strong></p><p><a href="Innaimo%20SF,%20et%20al.%20Identification%20of?BMS-200475?as%20a%20potent%20and%20selective%20inhibitor%20of%20hepatitis%20B%20virus.%20Antimicrob%20Agents%20Chemother.%201997%20Jul;41(7):1444-8." target="_blank">[</a><a href="Innaimo%20SF,%20et%20al.%20Identification%20of?BMS-200475?as%20a%20potent%20and%20selective%20inhibitor%20of%20hepatitis%20B%20virus.%20Antimicrob%20Agents%20Chemother.%201997%20Jul;41(7):1444-8." target="_blank">1</a><a href="Innaimo%20SF,%20et%20al.%20Identification%20of?BMS-200475?as%20a%20potent%20and%20selective%20inhibitor%20of%20hepatitis%20B%20virus.%20Antimicrob%20Agents%20Chemother.%201997%20Jul;41(7):1444-8." target="_blank">]</a>. Innaimo&nbsp;SF, et al. Identification of?BMS-200475?as a potent and selective inhibitor of hepatitisB virus.&nbsp;Antimicrob Agents Chemother.1997 Jul;41(7):1444-8. </p><p><a href="Rivkin%20A,%20et%20al.%20A%20review%20of%20entecavir%20in%20the%20treatment%20of%20chronic%20hepatitis%20B%20infection.%20Curr%20Med%20Res%20Opin.?2005%20Nov;21(11):1845-56." target="_blank">[</a><a href="Rivkin%20A,%20et%20al.%20A%20review%20of%20entecavir%20in%20the%20treatment%20of%20chronic%20hepatitis%20B%20infection.%20Curr%20Med%20Res%20Opin.?2005%20Nov;21(11):1845-56." target="_blank">2</a><a href="Rivkin%20A,%20et%20al.%20A%20review%20of%20entecavir%20in%20the%20treatment%20of%20chronic%20hepatitis%20B%20infection.%20Curr%20Med%20Res%20Opin.?2005%20Nov;21(11):1845-56." target="_blank">]</a>. Rivkin A, et al. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin.?2005 Nov;21(1 1):1845-56. <a href="Genovesi%20EV,%20et%20al.%20Efficacy%20of%20the%20carbocyclic%202'-deoxyguanosine%20nucleoside?BMS-200475?in%20the%20woodchuck%20model%20of%20hepatitis%20B%20virus%20infection.%20Antimicrob%20Agents%20Chemother.?1998%20Dec;42(12):3209-17.More:%20%09•J%20Exp.Clin%20Cancer%20Res.%202019%20Aug%2022;38(1):370.%20%09•J%20Infect.%202019%20Jun%2018.%20pii:%20S0163-4453(19)30187-2." target="_blank">[</a><a href="Genovesi%20EV,%20et%20al.%20Efficacy%20of%20the%20carbocyclic%202'-deoxyguanosine%20nucleoside?BMS-200475?in%20the%20woodchuck%20model%20of%20hepatitis%20B%20virus%20infection.%20Antimicrob%20Agents%20Chemother.?1998%20Dec;42(12):3209-17.More:%20%09•J%20Exp.Clin%20Cancer%20Res.%202019%20Aug%2022;38(1):370.%20%09•J%20Infect.%202019%20Jun%2018.%20pii:%20S0163-4453(19)30187-2." target="_blank">3</a><a href="Genovesi%20EV,%20et%20al.%20Efficacy%20of%20the%20carbocyclic%202'-deoxyguanosine%20nucleoside?BMS-200475?in%20the%20woodchuck%20model%20of%20hepatitis%20B%20virus%20infection.%20Antimicrob%20Agents%20Chemother.?1998%20Dec;42(12):3209-17.More:%20%09•J%20Exp.Clin%20Cancer%20Res.%202019%20Aug%2022;38(1):370.%20%09•J%20Infect.%202019%20Jun%2018.%20pii:%20S0163-4453(19)30187-2." target="_blank">]</a>. Genovesi EV, et al. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside?BMS-200475?in the woodchuck modelof hepatitisB virus infection. Antimicrob Agents Chemother.?1998 Dec;42(12):3209-17. </p><p></p><ul style="display: flex;"><li style="flex:1">More: </li><li style="flex:1">•Mol Pharm. 2018 Oct 30. </li></ul><p></p><p>•Virus Res.&nbsp;2019 Jul 31:197677. </p><p><strong>Relatedproducts </strong></p><p>Related Small Molecules: antiviral compounds <br>Vesatolimod #WPY994 (CAS :1228585-88-3 ; MW : 410.5) Bay 41-4109 (Bayer 41-4109) #AX5V71 (CAS :298708-81-3; MW:395.76) 4,5-Dicaffeoylquinicacid (Isochlorogenic acid C) #1M8596 (CAS : 57378-72-0; MW :516.4) Morphothiadin (GLS4) #AYHNG1 (CAS : 1092970-12-1; MW : 509.39) AB-423 #B2VBA1 (CAS : 1572510-80-5; MW ; 386.39) Squalamine (MSI-1256)#PM9151 (CAS : 148717-90-2; MW : 627.96) </p><p><strong>Ordering information </strong></p><p>Catalogsize quantities andpricesmay be found a<a href="/goto?url=http://www.interchim.eu/pp/5/life-sciences.html" target="_blank">t </a><a href="/goto?url=http://www.interchim.eu/pp/5/life-sciences.html" target="_blank">http://www.interchim.com</a>. Please inquirefor higherquantities(availability, shipmentconditions). Please contact InterBioTech – Interchim for anyother information </p><p>Hotline : +33(0)4 70 03 73 06 <a href="mailto:[email protected]" target="_blank">– </a><a href="mailto:[email protected]" target="_blank">[email protected] </a></p><p><strong>Disclaimer : </strong>Materials are&nbsp;sold <strong>for research use only</strong>, and are not intended for food,drug, household,or cosmetic use. Interchim<sup style="top: -0.25em;">® </sup>is not&nbsp;liable for any damage resulting from handling or contact with this product. </p><p>S01E </p><p>P.2 </p>